Pregnyl®

DRUG3 trials

Sponsors

Organon and Co, Universitair Ziekenhuis Brussel, Masonic Cancer Center, University of Minnesota

Conditions

Graft vs Host DiseaseIn Vitro FertilizationInfertilityOHSS

Phase 1

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

CompletedNCT02525029

Masonic Cancer Center, University of MinnesotaGraft vs Host Disease

Start: 2016-03-31End: 2022-04-30Updated: 2023-12-14

Phase 2

Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

CompletedNCT00702806

Organon and CoInfertility, In Vitro Fertilization

Start: 2001-07-01End: 2002-10-15Updated: 2024-08-15

Unknown Phase

Implantation Enhancement by Elective Cryopreservation of All Viable Embryos

CompletedNCT02148393

Universitair Ziekenhuis BrusselInfertility, OHSS

Start: 2014-05-31End: 2017-02-28Updated: 2018-03-09

Related Papers

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease.

2023-06-047 citations

Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd

Blood2021-11-056 citations

Validation of Amphiregulin As a Monitoring Biomarker during Treatment of Life-Threatening Acute Gvhd: A Secondary Analysis of 2 Prospective Clinical Trials

Blood2021-11-051 citations

Plasma Short Chain Fatty Acids As a Predictor of Response to Therapy for Life-Threatening Acute Graft-Versus-Host Disease

Blood2020-11-044 citations

The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial

Human Reproduction2020-08-1341 citations

Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor

Blood Advances2020-04-0129 citations